Consistent with our in vitro results, tumor growth was significantly suppressed in HSC-6 xenografts without AREG depletion (HSC-6-control groups) with erlotinib treatment (100 mg/kg) compared with vehicle control (p < 0.001) (Figure 6). This evidence concerns the gene AREG and neoplasm.